Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

  1. Nicolas Damond
  2. Fabrizio Thorel
  3. Julie S Moyers
  4. Maureen J Charron
  5. Patricia M Vuguin
  6. Alvin C Powers
  7. Pedro L Herrera  Is a corresponding author
  1. University of Geneva, Switzerland
  2. Eli Lilly and Company, United States
  3. Albert Einstein College of Medicine, United States
  4. Columbia University, United States
  5. Vanderbilt University, United States

Abstract

Glucagon secretion dysregulation in diabetes fosters hyperglycemia. Recent studies report that mice lacking glucagon receptor (Gcgr-/-) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-producing β-cells. Here, we show that diabetes prevention in STZ-treated Gcgr-/- animals requires remnant insulin action originating from spared residual β-cells: these mice indeed became hyperglycemic after insulin receptor blockade. Accordingly, Gcgr-/- mice developed hyperglycemia after induction of a more complete, diphtheria toxin (DT)-induced β-cell loss, a situation of near-absolute insulin deficiency similar to type 1 diabetes. In addition, glucagon deficiency did not impair the natural capacity of ncy did not impair the natural capacity α-cells to reprogram into insulin production after extreme β-cell loss. α-to-β-cell conversion was improved in Gcgr-/- mice as a consequence of α-cell hyperplasia. Collectively, these results indicate that glucagon antagonism could i) be a useful adjuvant therapy in diabetes only when residual insulin action persists, and ii) help devising future β-cell regeneration therapies relying upon α-cell reprogramming.

Article and author information

Author details

  1. Nicolas Damond

    Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète, University of Geneva, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  2. Fabrizio Thorel

    Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète, University of Geneva, Geneva, Switzerland
    Competing interests
    No competing interests declared.
  3. Julie S Moyers

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, United States
    Competing interests
    Julie S Moyers, J.S.M. is an employee and shareholder of Eli Lilly and Company.
  4. Maureen J Charron

    Departments of Biochemistry, Medicine, and Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, United States
    Competing interests
    No competing interests declared.
  5. Patricia M Vuguin

    Pediatric Endocrinology, Women's and Childrens Health, College of Physicians & Surgeons, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  6. Alvin C Powers

    Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Department of Molecular Physiology, Vanderbilt University, Nashville, United States
    Competing interests
    No competing interests declared.
  7. Pedro L Herrera

    Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète, University of Geneva, Geneva, Switzerland
    For correspondence
    Pedro.Herrera@unige.ch
    Competing interests
    No competing interests declared.

Ethics

Animal experimentation: All mice were housed and treated in accordance with the guidelines and regulations of the Direction Générale de la Santé, state of Geneva (license number GE/103/14).

Copyright

© 2016, Damond et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,627
    views
  • 851
    downloads
  • 66
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicolas Damond
  2. Fabrizio Thorel
  3. Julie S Moyers
  4. Maureen J Charron
  5. Patricia M Vuguin
  6. Alvin C Powers
  7. Pedro L Herrera
(2016)
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
eLife 5:e13828.
https://doi.org/10.7554/eLife.13828

Share this article

https://doi.org/10.7554/eLife.13828

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Amanda Mixon Blackwell, Yasaman Jami-Alahmadi ... Paul A Sigala
    Research Article

    Malaria parasites have evolved unusual metabolic adaptations that specialize them for growth within heme-rich human erythrocytes. During blood-stage infection, Plasmodium falciparum parasites internalize and digest abundant host hemoglobin within the digestive vacuole. This massive catabolic process generates copious free heme, most of which is biomineralized into inert hemozoin. Parasites also express a divergent heme oxygenase (HO)-like protein (PfHO) that lacks key active-site residues and has lost canonical HO activity. The cellular role of this unusual protein that underpins its retention by parasites has been unknown. To unravel PfHO function, we first determined a 2.8 Å-resolution X-ray structure that revealed a highly α-helical fold indicative of distant HO homology. Localization studies unveiled PfHO targeting to the apicoplast organelle, where it is imported and undergoes N-terminal processing but retains most of the electropositive transit peptide. We observed that conditional knockdown of PfHO was lethal to parasites, which died from defective apicoplast biogenesis and impaired isoprenoid-precursor synthesis. Complementation and molecular-interaction studies revealed an essential role for the electropositive N-terminus of PfHO, which selectively associates with the apicoplast genome and enzymes involved in nucleic acid metabolism and gene expression. PfHO knockdown resulted in a specific deficiency in levels of apicoplast-encoded RNA but not DNA. These studies reveal an essential function for PfHO in apicoplast maintenance and suggest that Plasmodium repurposed the conserved HO scaffold from its canonical heme-degrading function in the ancestral chloroplast to fulfill a critical adaptive role in organelle gene expression.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.